Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab versus Durvalumab + Tremelimumab plus Platinum-Based Chemotherapy in First-Line Metastatic NSCLC
jRCT2080223617Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2017
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by AstraZeneca. Started Aug 2017; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223617.